Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas.

NCT00484341 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Adult Soft Tissue Sarcoma

Interventions

DRUG: low-dose NGR-hTNF
DRUG: high-dose NGR-hTNF
DRUG: Doxorubicin

Sponsor

AGC Biologics S.p.A.